## Janus Henderson VIT Global Research Portfolio

Schedule of Investments (unaudited)
March 31, 2024

|  | Shares or Principal Amounts | Value |
| :---: | :---: | :---: |
| Common Stocks- 98.1\% |  |  |
| Aerospace \& Defense - 2.7\% |  |  |
| Airbus SE | 22,362 | \$4,118,097 |
| BAE Systems PLC | 857,799 | 14,607,674 |
| General Dynamics Corp | 20,167 | 5,696,976 |
|  |  | 24,422,747 |
| Banks - 5.8\% |  |  |
| BNP Paribas SA | 135,076 | 9,596,248 |
| HDFC Bank Ltd | 239,844 | 4,164,035 |
| JPMorgan Chase \& Co | 95,113 | 19,051,134 |
| Natwest Group PLC | 2,711,691 | 9,085,051 |
| UniCredit SpA | 265,604 | 10,077,905 |
|  |  | 51,974,373 |
| Beverages-3.1\% |  |  |
| Constellation Brands Inc - Class A | 38,771 | 10,536,407 |
| Monster Beverage Corp* | 167,988 | 9,958,329 |
| Pernod Ricard SA | 45,967 | 7,435,226 |
|  |  | 27,929,962 |
|  |  |  |
| AbbVie Inc | 32,173 | 5,858,703 |
| Amgen Inc | 14,077 | 4,002,373 |
| Argenx SE (ADR)* | 5,684 | 2,237,905 |
| Ascendis Pharma A/S (ADR)* | 14,714 | 2,224,315 |
| Madrigal Pharmaceuticals Inc* | 3,815 | 1,018,758 |
| Sarepta Therapeutics Inc* | 16,577 | 2,146,058 |
| Vertex Pharmaceuticals Inc* | 9,156 | 3,827,300 |
| Capital Markets - 3.3\% 21,315,412 |  |  |
|  |  |  |
| Ares Management Corp - Class A | 38,377 | 5,103,373 |
| Blackstone Group Inc | 44,951 | 5,905,213 |
| Charles Schwab Corp | 94,695 | 6,850,236 |
| LPL Financial Holdings Inc | 22,335 | 5,900,907 |
| Morgan Stanley | 61,485 | 5,789,428 |
|  |  | 29,549,157 |
| Chemicals - 3.2\% |  |  |
| Linde PLC | 37,388 | 17,359,996 |
| Sherwin-Williams Co | 32,145 | 11,164,923 |
|  |  | 28,524,919 |
| Consumer Finance - 1.2\% |  |  |
| Capital One Financial Corp | 48,690 | 7,249,454 |
| OneMain Holdings Inc | 60,305 | 3,080,982 |
|  |  | 10,330,436 |
| Diversified Financial Services - 4.1\% |  |  |
| Apollo Global Management Inc | 54,288 | 6,104,686 |
| Global Payments Inc | 30,308 | 4,050,967 |
| Mastercard Inc - Class A | 29,321 | 14,120,114 |
| Visa Inc | 44,433 | 12,400,362 |
|  |  | 36,676,129 |
| Electronic Equipment, Instruments \& Components - 1.7\% |  |  |
| Hexagon AB - Class B | 994,634 | 11,775,711 |
| Keysight Technologies Inc* | 20,996 | 3,283,355 |
|  |  | 15,059,066 |
| Entertainment - 1.9\% [ |  |  |
| Liberty Media Corp-Liberty Formula One - Series C* | 132,527 | 8,693,771 |
| Netflix Inc* | 14,111 | 8,570,034 |
|  |  | 17,263,805 |
| Health Care Equipment \& Supplies - 2.3\% 1-263,805 |  |  |
| Abbott Laboratories | 22,468 | 2,553,713 |
| Boston Scientific Corp* | 106,578 | 7,299,527 |
| Edwards Lifesciences Corp* | 45,308 | 4,329,633 |
| Hoya Corp | 14,200 | 1,767,026 |
| Intuitive Surgical Inc* | 3,625 | 1,446,701 |
| Stryker Corp | 9,738 | 3,484,938 |
|  |  | 20,881,538 |
| Health Care Providers \& Services - 1.6\% |  |  |
| AmerisourceBergen Corp | 12,860 | 3,124,851 |
| HCA Healthcare Inc | 8,952 | 2,985,761 |
| Humana Inc | 4,385 | 1,520,367 |


|  | Shares or Principal Amounts | Value |
| :---: | :---: | :---: |
| Common Stocks- (continued) |  |  |
| Health Care Providers \& Services- (continued) |  |  |
| UnitedHealth Group Inc | 13,649 | \$6,752,160 |
|  |  | 14,383,139 |
| Hotels, Restaurants \& Leisure - 2.7\% |  |  |
| Booking Holdings Inc | 2,522 | 9,149,513 |
| Entain PLC | 292,966 | 2,947,923 |
| McDonald's Corp | 44,155 | 12,449,502 |
|  |  | 24,546,938 |
| Independent Power and Renewable Electricity Producers - 2.3\% |  |  |
| RWE AG | 45,268 | 1,536,213 |
| Vistra Energy Corp | 280,318 | 19,524,149 |
|  |  | 21,060,362 |
| Insurance-3.2\% |  |  |
| AIA Group Ltd | 476,000 | 3,195,957 |
| Arthur J Gallagher \& Co | 24,481 | 6,121,229 |
| Beazley PLC | 546,585 | 4,590,166 |
| Intact Financial Corp | 13,333 | 2,166,120 |
| Progressive Corp/The | 61,432 | 12,705,366 |
|  |  | 28,778,838 |
| Interactive Media \& Services - $6.1 \%$ |  |  |
| Alphabet Inc - Class C* | 200,565 | 30,538,027 |
| Meta Platforms Inc-Class A | 50,282 | 24,415,934 |
|  |  | 54,953,961 |
| Life Sciences Tools \& Services - 0.6\% |  |  |
| Thermo Fisher Scientific Inc | 9,204 | 5,349,457 |
| Machinery - 3.7\% |  |  |
| Alstom SA* | 66,831 | 1,018,642 |
| Atlas Copco AB - Class A | 604,761 | 10,217,142 |
| Deere \& Co | 24,607 | 10,107,079 |
| Parker-Hannifin Corp | 21,083 | 11,717,721 |
|  |  | 33,060,584 |
| Metals \& Mining - 2.1\% |  |  |
| Freeport-McMoRan Inc | 116,337 | 5,470,166 |
| Rio Tinto PLC | 54,505 | 3,450,667 |
| Teck Resources Ltd | 209,431 | 9,587,066 |
|  |  | 18,507,899 |
| Multiline Retail - 3.0\% |  |  |
| Amazon.com Inc* | 146,595 | 26,442,806 |
| Oil, Gas \& Consumable Fuels - 5.5\% |  |  |
| Canadian Natural Resources Ltd | 115,830 | 8,836,912 |
| Cheniere Energy Inc | 17,261 | 2,783,854 |
| ConocoPhillips | 60,098 | 7,649,273 |
| EOG Resources Inc | 42,606 | 5,446,751 |
| Marathon Petroleum Corp | 58,016 | 11,690,224 |
| Suncor Energy Inc | 133,717 | 4,935,405 |
| TC Energy Corp\# | 126,390 | 5,080,236 |
| TotalEnergies SE | 45,097 | 3,087,576 |
|  |  | 49,510,231 |
| Personal Products - 1.7\% |  |  |
| Unilever PLC | 303,836 | 15,246,862 |
| Pharmaceuticals - 5.1\% |  |  |
| AstraZeneca PLC | 56,664 | 7,635,189 |
| Eli Lilly \& Co | 10,481 | 8,153,799 |
| Merck \& Co Inc | 64,652 | 8,530,831 |
| Novartis AG | 55,438 | 5,371,651 |
| Novo Nordisk A/S - Class B | 69,808 | 8,904,996 |
| Roche Holding AG | 12,814 | 3,264,252 |
| Sanofi | 43,003 | 4,219,400 |
|  |  | 46,080,118 |
| Real Estate Management \& Development - 0.8\% |  |  |
| CoStar Group Inc* | 75,972 | 7,338,895 |
| Road \& Rail - 0.5\% |  |  |
| Uber Technologies Inc* | 58,940 | 4,537,791 |
| Semiconductor \& Semiconductor Equipment - 10.6\% |  |  |
| Advanced Micro Devices Inc* | 40,726 | 7,350,636 |
| Applied Materials Inc | 14,483 | 2,986,829 |
| ASML Holding NV | 15,568 | 14,982,924 |
| Broadcom Inc | 5,874 | 7,785,458 |
| Lam Research Corp | 6,021 | 5,849,823 |
| Marvell Technology Inc | 47,748 | 3,384,378 |
| NVIDIA Corp | 43,158 | 38,995,843 |
| Taiwan Semiconductor Manufacturing Co Ltd | 473,000 | 11,367,492 |
| Texas Instruments Inc | 10,550 | 1,837,916 |
|  |  | 94,541,299 |


|  | Shares or Principal Amounts | Value |
| :---: | :---: | :---: |
| Common Stocks- (continued) |  |  |
| Software - 8.3\% |  |  |
| Adobe Inc* | 9,689 | \$4,889,069 |
| Constellation Software Inc/Canada | 1,391 | 3,799,985 |
| Microsoft Corp | 119,427 | 50,245,327 |
| ServiceNow Inc* | 2,502 | 1,907,525 |
| Synopsys Inc* | 16,520 | 9,441,180 |
| Workday Inc-Class A* | 15,616 | 4,259,264 |
|  |  | 74,542,350 |
| Specialty Retail - 1.7\% |  |  |
| O'Reilly Automotive Inc* | 9,288 | 10,485,037 |
| TJX Cos Inc | 43,406 | 4,402,237 |
|  |  | 14,887,274 |
| Technology Hardware, Storage \& Peripherals - 2.9\% |  |  |
| Apple Inc | 151,675 | 26,009,229 |
| Textiles, Apparel \& Luxury Goods - 1.1\% |  |  |
| LVMH Moet Hennessy Louis Vuitton SE | 7,130 | 6,412,108 |
| Moncler SpA | 40,699 | 3,037,147 |
|  |  | 9,449,255 |
| Trading Companies \& Distributors - 1.9\% |  |  |
| Ferguson PLC | 78,390 | 17,137,859 |
| Wireless Telecommunication Services - 1.0\% |  |  |
| T-Mobile US Inc | 53,167 | 8,677,918 |
| Total Common Stocks (cost \$479,936,098) |  | 878,970,609 |
| Preferred Stocks-1.3\% |  |  |
| Automobiles - 1.3\% |  |  |
| Dr Ing hc F Porsche AG (144A) (cost \$10,341,505) | 120,220 | 11,967,015 |
| Private Placements-0\% |  |  |
| Health Care Providers \& Services - 0\% |  |  |
| API Holdings Private Ltd*, ¢,§ (cost \$2,347,416) | 3,231,470 | 187,539 |
| Warrants-0\% |  |  |
| Software - 0\% |  |  |
| Constellation Software Inc/Canada, expires 3/31/40*,¢ (cost \$0) | 1,355 | 0 |
| Investment Companies- 0.4\% |  |  |
| Money Markets - 0.4\% |  |  |
| Janus Henderson Cash Liquidity Fund LLC, $5.3830 \%{ }^{\circ}$, ¢ (cost \$3,072,656) | 3,072,042 | 3,072,656 |
| Investments Purchased with Cash Collateral from Securities Lending- 0.5\% |  |  |
| Investment Companies - 0.4\% |  |  |
| Janus Henderson Cash Collateral Fund LLC, $5.2800 \%{ }^{\text {a }, ~}$ | 3,788,273 | 3,788,273 |
| Time Deposits - 0.1\% |  |  |
| Royal Bank of Canada, 5.3100\%, 4/1/24 | \$947,068 | 947,068 |
| Total Investments Purchased with Cash Collateral from Securities Lending (cost \$4,735,341) |  | 4,735,341 |
| Total Investments (total cost \$500,433,016) - 100.3\% |  | 898,933,160 |
| Liabilities, net of Cash, Receivables and Other Assets - (0.3)\% |  | (3,005,529) |
| Net Assets - 100\% |  | \$895,927,631 |

## Summary of Investments by Country - (Long Positions) (unaudited)

|  |  | $\%$ of <br> Investment <br> Securities |
| :--- | ---: | :---: |
| Country | Value | $73.9 \%$ |
| United States | $\$ 664,797,382$ | 4.7 |
| United Kingdom | $42,316,670$ | 4.0 |
| France | $35,887,297$ | 3.8 |
| Canada | $34,405,724$ | 3.4 |
| Netherlands | $30,229,786$ | 2.4 |
| Sweden | $21,992,853$ | 1.5 |
| Germany | $13,503,228$ | 1.5 |
| Italy | $13,115,052$ | 1.3 |
| Taiwan | $11,367,492$ | 1.2 |
| Denmark | $11,129,311$ | 1.0 |
| Switzerland | $8,635,903$ | 0.5 |
| India | $4,351,574$ | 0.4 |
| Hong Kong | $3,195,957$ | 0.2 |
| Belgium | $2,237,905$ | 0.2 |
| Japan | $1,767,026$ | $100.0 \%$ |
| Total | $\$ 898,933,160$ |  |

## Schedules of Affiliated Investments - (\% of Net Assets)



Schedule of Total Return Swaps

|  | Return Received by the Portfolio | Payment Frequency | Termination Date | Notional <br> Amount |  | Swap <br> Contracts, at Value and Unrealized Appreciation/ (Depreciation) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  |  |  |  |  |
| Counterparty/ |  |  |  |  |  |  |  |
| Return Paid |  |  |  |  |  |  |  |
| by the Portfolio |  |  |  |  |  |  |  |
| UBS AG, London Branch: |  |  |  |  |  |  |  |
| Euro short-term rate $+0.55 \%$ | Ryanair Holdings PLC | At Maturity | 2/24/25 | 3,680,728 | EUR | \$ | 599,029 |

Average Ending Monthly Value of Derivative Instruments During the Period Ended March 31, 2024

Total return swaps:
Average notional amount
\$2,760,546

## Notes to Schedule of Investments (unaudited)

American Depositary Receipt

Limited Liability Company
PLC
Public Limited Company

144A Securities sold under Rule 144A of the Securities Act of 1933, as amended, are subject to legal and/or contractual restrictions on resale and may not be publicly sold without registration under the 1933 Act. Unless otherwise noted, these securities have been determined to be liquid under guidelines established by the Board of Trustees. The total value of 144 A securities as of the period ended March 31,2024 is $\$ 11,967,015$, which represents $1.3 \%$ of net assets.

* Non-income producing security

Rate shown is the 7-day yield as of March 31, 2024.
\# Loaned security; a portion of the security is on loan at March 31, 2024.
$\Phi \quad$ Security is valued using significant unobservable inputs. The total value of Level 3 securities as of the period ended March 31, 2024 is $\$ 187,539$, which represents $0.0 \%$ of net assets.
£ The Portfolio may invest in certain securities that are considered affiliated companies. As defined by the Investment Company Act of 1940, as amended, an affiliated company is one in which the Portfolio owns 5\% or more of the outstanding voting securities, or a company which is under common ownership or control.
$\Delta \quad$ Net of income paid to the securities lending agent and rebates paid to the borrowing counterparties.
$\S \quad$ Schedule of Restricted Securities (as of March 31, 2024)

|  | Acquisition |  |  |  |  | Value as a \% of Net |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Date |  | Cost |  | Value |  |
| API Holdings Private Ltd | 9/27/21 | \$ | 2,347,416 | \$ | 187,539 | 0.0\% |

The Portfolio has registration rights for certain restricted securities held as of March 31, 2024. The issuer incurs all registration costs.

The following is a summary of the inputs that were used to value the Portfolio's investments in securities and other financial instruments as of March 31, 2024.

## Valuation Inputs Summary

| Level 1- | Level 2- <br> Other Significant | Level 3- <br> Significant <br> Observable Inputs |
| :--- | :---: | ---: |
| Quoted Prices |  |  |

## Assets

Investments In Securities:

| Common Stocks |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Pharmaceuticals | \$ | 37,175,122 | \$ | 8,904,996 | \$ | - |
| All Other |  | 832,890,491 |  | - |  | - |
| Preferred Stocks |  | 11,967,015 |  | - |  | - |
| Private Placements |  | - |  | - |  | 187,539 |
| Warrants |  | - |  | - |  | 0 |
| Investment Companies |  | - |  | 3,072,656 |  | - |
| Investments Purchased with Cash Collateral from Securities |  |  |  |  |  |  |
| Lending |  | - |  | 4,735,341 |  | - |
| Total Investments in Securities | \$ | 882,032,628 | \$ | 16,712,993 | \$ | 187,539 |
| Other Financial Instruments ${ }^{(a)}$ : |  |  |  |  |  |  |
| OTC Swaps |  | - |  | 599,029 |  | - |
| Total Assets | \$ | 882,032,628 | \$ | 17,312,022 | \$ | 187,539 |

(a) Other financial instruments may include forward foreign currency exchange contracts, futures, written options, written swaptions, and swap contracts. Forward foreign currency exchange contracts, futures contracts, and swap contracts are reported at their unrealized appreciation/(depreciation) at measurement date, which represents the change in the contract's value from trade date. Written options and written swaptions are reported at their market value at measurement date.

## Investment Valuation

Portfolio holdings are valued in accordance with policies and procedures established by the Adviser pursuant to Rule $2 a-5$ under the 1940 Act and approved by and subject to the oversight of the Trustees (the "Valuation Procedures"). Equity securities traded on a domestic securities exchange are generally valued at readily available market quotations, which are (i) the official close prices or (ii) last sale prices on the primary market or exchange in which the securities trade. If such price is lacking for the trading period immediately preceding the time of determination, such securities are generally valued at their current bid price. Equity securities that are traded on a foreign exchange are generally valued at the closing prices on such markets. In the event that there is no current trading volume on a particular security in such foreign exchange, the bid price from the primary exchange is generally used to value the security. Foreign securities and currencies are converted to U.S. dollars using the current spot USD dollar exchange rate in effect at the close of the New York Stock Exchange ("NYSE"). The Adviser will determine the market value of individual securities held by it by using prices provided by one or more Adviser-approved professional pricing services or, as needed, by obtaining market quotations from independent broker-dealers. Most debt securities are valued in accordance with the evaluated bid price supplied by the pricing service that is intended to reflect market value. The evaluated bid price supplied by the pricing service is an evaluation that may consider factors such as security prices, yields, maturities and ratings. Certain short-term securities maturing within 60 days or less may be evaluated and valued on an amortized cost basis provided that the amortized cost determined approximates market value. Securities for which market quotations or evaluated prices are not readily available or deemed unreliable are valued at fair value determined in good faith by the Adviser pursuant to the Valuation Procedures. Circumstances in which fair valuation may be utilized include, but are not limited to: (i) a significant event that may affect the securities of a single issuer, such as a merger, bankruptcy, or significant issuer-specific development; (ii) an event that may affect an entire market, such as a natural disaster or significant governmental action; (iii) a nonsignificant event such as a market closing early or not opening, or a security trading halt; and (iv) pricing of a nonvalued security and a restricted or nonpublic security. Special valuation considerations may apply with respect to "odd-lot" fixed-income transactions which, due to their small size, may receive evaluated prices by pricing services which reflect a large block trade and not what actually could be obtained for the odd-lot position. The value of the securities of other mutual funds held by the Portfolio, if any, will be calculated using the NAV of such mutual funds, and the prospectuses for such mutual funds explain the circumstances under which they use fair valuation and the effects of using fair valuation. The value of the securities of any cash management pooled investment vehicles that operate as money market funds held by the Portfolio, if any, will be calculated using the NAV of such funds.

## Valuation Inputs Summary

FASB ASC 820, Fair Value Measurements and Disclosures ("ASC 820"), defines fair value, establishes a framework for measuring fair value, and expands disclosure requirements regarding fair value measurements. This standard emphasizes that fair value is a market-based measurement that should be determined based on the assumptions that market participants would use in pricing an asset or liability and establishes a hierarchy that prioritizes inputs to valuation techniques used to measure fair value. These inputs are summarized into three broad levels:

Level 1 - Unadjusted quoted prices in active markets the Portfolio has the ability to access for identical assets or liabilities.

Level 2 - Observable inputs other than unadjusted quoted prices included in Level 1 that are observable for the asset or liability either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.

[^0]There have been no significant changes in valuation techniques used in valuing any such positions held by the Portfolio since the beginning of the fiscal period.
The inputs or methodology used for fair valuing securities are not necessarily an indication of the risk associated with investing in those securities. The summary of inputs used as of March 31, 2024 to fair value the Portfolio's investments
in securities and other financial instruments is included in the "Valuation Inputs Summary" in the Notes to Schedule of Investments.
The Portfolio did not hold a significant amount of Level 3 securities as of March 31, 2024.

For additional information on the Portfolio, please refer to the Portfolio's most recent semiannual or annual shareholder report.


[^0]:    Assets or liabilities categorized as Level 2 in the hierarchy generally include: debt securities fair valued in accordance with the evaluated bid or ask prices supplied by a pricing service; securities traded on OTC markets and listed securities for which no sales are reported that are fair valued at the latest bid price (or yield equivalent thereof) obtained from one or more dealers transacting in a market for such securities or by a pricing service approved by the Portfolio's Trustees; certain short-term debt securities with maturities of 60 days or less that are fair valued at amortized cost; and equity securities of foreign issuers whose fair value is determined by using systematic fair valuation models provided by independent third parties in order to adjust for stale pricing which may occur between the close of certain foreign exchanges and the close of the NYSE. Other securities that may be categorized as Level 2 in the hierarchy include, but are not limited to, preferred stocks, bank loans, swaps, investments in unregistered investment companies, options, and forward contracts.
    Level 3 - Unobservable inputs for the asset or liability to the extent that relevant observable inputs are not available, representing the Portfolio's own assumptions about the assumptions that a market participant would use in valuing the asset or liability, and that would be based on the best information available.

